GBM patients with low SERBP1 expression had markedly longer survival (17.41 ± 1.93 months, 95% CI 13.48–21.35) than those with high SERBP1 expression (10.52 ± 0.97 months, 95% CI 8.59–12.46) (P = 0.0006) (Fig. 1e). This evidence concerns the gene SERBP1 and glioblastoma.